Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Hans Rammensee

Harpreet Singh

Immatics N.V.

Genenta Science is a clinical stage immuno-oncology company developing a cell-based platform that harnesses the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors. The platform is not restricted by tumor type or target antigen and enables sustained targeted expression of therapeutic payloads inside the tumor microenvironment.

Metric
Company Name	Immatics N.V.	Genenta Science
Symbol	IMTX
MSH ID	COM:IMMATICS	COM:GENENTA
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	DE	IT
Stage
Employee Count	432
Website	immatics.com	genenta.com
LinkedIn
Founders

Metric
Market Cap	1.25B
Enterprise Value
Monthly Web Traffic	5.82K
Web Traffic Growth	-0.48
Valuation
Raised Capital

Metric
Revenue	57.03M
Revenue (LTM)
Revenue (NTM)
Gross Profit	57.03M
EBITDA	-85.18M
Operating Income	-107.44M
Net Income	-102.45M
EPS	-1.27
Diluted EPS	-1.27
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-0.09
Operating Profit Margin	-0.86
EBITDA Margin	-1.49
Net Profit Margin	-1.04
Return on Equity	-0.23
Return on Assets	-0.12
Return on Capital Employed	-0.18

COM:IMMATICS

Immatics

Last Close

7.58

22/11 21:00

Market Cap

1.25B

Beta: -

Volume Today

535.37K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-11.05
P/B Ratio	3.54
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	19.76
EV Multiple	-12.03

Metric
Days Sales Outstanding	6.70
Days Payables Outstanding
Days Inventory Outstanding	47.73
Operating Cycle	71.44
Cash Conversion Cycle	47.86
Asset Turnover	0.17

Metric
Operating Cash Flow	19.25M
Free Cash Flow	-13.44M
Cash Flow to Debt	1.18
Operating Cash Flow/Sales	0.34
Free Cash Flow Yield	-0.11

Metric
Cash & Equivalents	230.76M
Accounts Receivable	-3.15M
Inventory	11.22M
Goodwill
Debt to Capitalization	0.08
Debt to Assets	0.04
Current Ratio	3.18
Quick Ratio	3.95

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.29
R&D to Revenue	1.50
SG&A to Revenue	0.46